DeepMed Research

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-29

Last Posted Date: 2013-07-24

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT00002680

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-28

Last Posted Date: 2009-08-25

Lead Sponsor: Yale University

Target Recruit Count: 47

Registration Number: NCT00004923

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸
Bennett Cancer Center, Stamford, Connecticut, United States

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Phase 1

Terminated

Conditions: Childhood Langerhans Cell Histiocytosis
Islet Cell Tumor
Kidney Cancer
Lung Cancer
Neoplastic Syndrome
Neuroendocrine Carcinoma of the Skin
Pheochromocytoma
Gastrointestinal Carcinoid Tumor
Head and Neck Cancer
Intraocular Melanoma

First Posted Date: 2004-03-26

Last Posted Date: 2014-07-02

Lead Sponsor: Yale University

Target Recruit Count: 35

Registration Number: NCT00002947

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-03-26

Last Posted Date: 2020-08-17

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT00002950

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

Not Applicable

Completed

Conditions: Child Development Disorders, Pervasive

Interventions: Drug: Risperidone
Behavioral: Behavior Therapy

First Posted Date: 2004-03-25

Last Posted Date: 2013-08-16

Lead Sponsor: Yale University

Target Recruit Count: 124

Registration Number: NCT00080145

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

Motivational Enhancement for Spanish Speaking Individuals - 1

Phase 3

Completed

Conditions: Substance-Related Disorders

First Posted Date: 2004-02-23

Last Posted Date: 2017-01-12

Lead Sponsor: Yale University

Target Recruit Count: 463

Registration Number: NCT00078169

Locations: 🇺🇸
The Life Link, Santa Fe, New Mexico, United States
🇺🇸
Changepoint - Cedar Hills Blvd, Portland, Oregon, United States
🇺🇸
Island Grove RTC, Greeley, Colorado, United States

and more 4 locations

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-02-06

Last Posted Date: 2009-08-26

Lead Sponsor: Yale University

Target Recruit Count: 89

Registration Number: NCT00002679

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Combination Nicotine Replacement for Alcoholic Smokers

Phase 4

Completed

Conditions: Smoking
Alcoholism

Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation
Drug: Nicoderm CQ nicotine patch
Drug: Placebo gum
Drug: Nicotine gum - Nicorette®

First Posted Date: 2003-07-15

Last Posted Date: 2021-08-13

Lead Sponsor: Yale University

Target Recruit Count: 96

Registration Number: NCT00064844

Locations: 🇺🇸
VA Connecticut Healthcare System, Newington, Connecticut, United States

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-02

Lead Sponsor: Yale University

Registration Number: NCT00002948

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2009-08-25

Lead Sponsor: Yale University

Target Recruit Count: 28

Registration Number: NCT00004924

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸
Northwestern Connecticut Oncology-Hematology Associates - Torrington, Torrington, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy